Navigation Links
Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 14, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the presentation of additional data related to its immuno-inflammatory product candidates, CRx-102 and CRx-139, at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology meeting, June 13-16, 2007 in Barcelona, Spain.

CRx-102

In a poster entitled "Inhibition of Macrophage and Chondrocyte Inflammatory Mediators by CRx-102, a Novel Synergistic Combination Drug Candidate", Fraser, et.al. further insights into the novel mechanism of action of CRx-102 were unveiled. The synergistic combination of the two agents, dipyridamole and prednisolone, was found to modulate converging intracellular signaling pathways to synergistically inhibit key inflammatory modulators and mediators (TNF-alpha, MIP-1a, RANTES, MDC, IL-6 and MMP-9) that control disease progression and contribute directly to disease pathology.

In a poster entitled "Response and State-Attainment Criteria in Hand OA: Analysis from a Placebo-Controlled Clinical Trial of CRx-102, A Novel Synergistic Combination Therapy", Kvien, et.al., reliable outcome measures to evaluate clinically meaningful benefits of CRx-102 treatment in osteoarthritis (OA) from an individual patient perspective were evaluated. CRx-102 consistently showed clinically meaningful benefit across these outcome measures and responder analyses:

-- BLISS response of individual pain of less than or equal to 20 (27% CRx-102 vs. 6% placebo, p=0.035)

-- Modified OMERACT-OARSI response (50% CRx-102 vs. 30% placebo, p=NSS)

-- AUSCAN 20/50/70 (AUSCAN 70: 23% CRx-102 vs. 3% placebo, p=0.037)

In a satellite symposium presentation, Dr. John Kirwan, of the Bristol Royal Infirmary in the UK and principal investigator in the CRx-102 phase 2a rheumatoid arthritis (RA) trial, gave a talk entitled "A Therapy Rejuvenation: Glucocorticoids in Arth
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
4. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
5. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
6. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:10/22/2014)... -- Moms are ready to live the "measured life" ... kids, according to the results of the BabyCenter® U.S. ... for Moms, the latest installment in BabyCenter,s 21 st ... and parenting web and mobile destination worldwide, conducted the ... say they can,t think of a reason not to ...
(Date:10/22/2014)... Oct. 22, 2014 AVACEN Medical announced today ... 510 (k) OTC clearance by the U.S. Food and ... be marketed over the Internet for: the temporary ... and minor strains and sprains . Logo ... 100 (MSRP $2495) is a sophisticated medical device incorporating ...
(Date:10/22/2014)... Inc. (NYSE: CRY ), a leading medical ... vascular surgery, announced today that James Patrick (Pat) ... elected to the Company,s Board of Directors, effective October ... Executive Chairman of CryoLife, stated, "Since joining the Company in ... who is well positioned to maximize CryoLife,s potential.  His ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively.  Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...
... Merz Pharmaceuticals, LLC, today announced that data from ... Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from ... will be presented at the 115th Annual Meeting of ... These data include an extension of the ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... quickly add weight and length may be showing a genetic ... In adults, certain genes have been linked to increased body ... in fat and lean muscle, the researchers said. At ... taller. By ages 2 and 3, however, these genes were ...
(Date:10/22/2014)... By Tara Haelle ... -- Binge drinking among young adult men may lead to ... binge drinking didn,t cause a similar rise in blood pressure ... study. In fact, when young adult women drank lightly or ... half, the study found. "This finding parallels studies in ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. ... officially tightened guidelines for health workers treating Ebola patients, now ... of a respirator at all times. The U.S. Centers ... rules after two Dallas nurses contracted Ebola while caring for ... national Thomas Eric Duncan. Nina Pham is currently being treated ...
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... as medication rid brain of matted protein, researchers say , , ... aims to reduce the clogging "tangles" in the brain cells ... researchers report. , Further studies are necessary to confirm whether ... seems, or whether it needs to be given as part ...
... Former U.S. Surgeon General,Julius B. Richmond, MD, FAAP, a ... Sunday, July 27, 2008, of,cancer at his home near ... President Carter,s Assistant Secretary for,Health and as U.S. Surgeon ... reinvigorated tobacco control efforts through the release of,the 1979 ...
... Md., July 29 Sanaria Inc., a,privately ... University of,Maryland Biotechnology Institute (UMBI) announced the ... (SBIR) Grant from the,National Institute of Allergy ... of Health. The grant will support research ...
... Genomma Lab,Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma" ... personal care products,company announced yesterday that it had ... UNIGASTROZOL, from Unipharm de Mexico, S.A. de,C.V. This ... control of,gastrointestinal symptoms that are produced by excessive ...
... safety, reliable results , , TUESDAY, July 29 (HealthDay News) ... cancer care and research, but most tests aren,t administered ... Medical Center researchers. , In cancer care, exercise tests ... cancer patients. In cancer research, exercise tests are most ...
... Corporate Officer of Gillette, brings 38 years of ... experience in consumer products industry, CHICAGO, ... announced today that Peter Klein has joined the,firm as a ... the global consumer products,industry and was most recently senior vice ...
Cached Medicine News:Health News:'De-Tangling' Alzheimer's Drug Shows Promise 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 3Health News:'De-Tangling' Alzheimer's Drug Shows Promise 4Health News:Former U.S. Surgeon General Julius B. Richmond, 91 2Health News:Former U.S. Surgeon General Julius B. Richmond, 91 3Health News:Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant 2Health News:Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant 3Health News:Genomma Lab Internacional Acquires UNIGASTROZOL 2Health News:Exercise Testing for Cancer Fails to Follow Guidelines 2Health News:The Cambridge Group Names Peter Klein a Director 2
... Featuring an expanded database containing over ... identification cards, VITEK 2 Compact offers ... amount of time (2 to 14 ... of microorganisms that contaminate production areas ...
... transmitting data from multiple sources is ... Dawnings ResultNet/Plus software allows you to ... your communications network., ,ResultNet/Plus eliminates the ... from largescale or multi-site laboratories to ...
... Software is a powerful Java-based interface ... to control laboratory instrument connections and ... used in two applications: embedded in ... on a network PC station. Within ...
Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
Medicine Products: